FrancophonIA/ELRC3.0 huggingface dataset:
English: Horse Intramuscular use Vial (type I glass) closed with a halogenobutyl rubber stopper and aluminium cap.
Estonian: Intramuskulaarne Viaal (I tüübi klaas) suletud halogeenbutüülkummist korgiga ja aluminiumkapsliga
English: Content Package size
Estonian: Sisaldus Pakendi suurus Keeluajad
English: --1 Equine influenza virus strains:
Estonian: --1 Hobuste gripiviiruse tüved:
English: Packaging
Estonian: EL number
English: 1 dose 10 glass vials
Estonian: 1 doos 10 klaasviaali
English: 1 dose 1 pre-filled syringe
Estonian: 1 doos 1 eeltäidetud süstal
English: They involved over 5,000 people from 4 years of age.
Estonian: Uuringutes osales üle 5000 vähemalt 4-aastast inimest.
English: Further information on Flucelvax Tetra can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Flucelvax-tetra
Estonian: Lisateave Flucelvax Tetra kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Flucelvax-tetra
English: Each year, the World Health Organization (WHO) makes recommendations on which flu strains should be included in vaccines for the upcoming flu season in the northern hemisphere.
Estonian: Maailma Terviseorganisatsioon (WHO) avaldab igal aastal soovitused viirusetüvede kohta, mis peaksid sisalduma põhjapoolkera järgmise gripihooaja vaktsiinides.
English: The European Medicines Agency therefore decided that Flucelvax Tetra's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Flucelvax Tetra kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: What measures are being taken to ensure the safe and effective use of Flucelvax Tetra?
Estonian: Mis meetmed võetakse, et tagada Flucelvax Tetra ohutu ja efektiivne kasutamine?
English: The recommended dose is one single injection into a muscle (0.5 ml), preferably in the upper arm.
Estonian: Soovitatav annus on üks ühekordne süst (0,5 ml) eelistatavalt õlavarde.
English: The studies assessed the ability of the vaccines to stimulate an immune response against influenza, by measuring the production of protective antibodies.
Estonian: Uuringutes hinnati vaktsiinide võimet stimuleerida immuunvastust gripi vastu, määrates kaitsvate antikehade teket.
English: The most common side effects with Flucelvax Tetra (which may affect more than 1 in 10 people) are pain at the injection site, reddening of the skin and hardening at the injection site, headache, tiredness and muscle pain.
Estonian: Flucelvax Tetra kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on süstekoha valu, naha punetus ja kõvenemine süstekohal, peavalu, väsimus ja lihasvalu.
English: Side effects reported with Flucelvax Tetra are carefully evaluated and any necessary action taken to protect patients.
Estonian: Flucelvax Tetra kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Flucelvax Tetra have been included in the summary of product characteristics and the package leaflet.
Estonian: Flucelvax Tetra ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: One of the vaccines was Optaflu, a previously authorised vaccine which contains three of the four strains of influenza in Flucelvax Tetra and whose effectiveness in preventing flu is well established.
Estonian: Üks vaktsiinidest oli Optaflu, mis on varem lubatud vaktsiin, mis sisaldab kolme neljast viirusetüvest Flucelvax Tetras ja mille efektiivsus gripi ennetamisel on hästi tõestatud.
English: For more information about using Flucelvax Tetra, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet ravimi Flucelvax Tetra kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: As for all medicines, data on the use of Flucelvax Tetra are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse ravimi Flucelvax Tetra kasutamise kohta pidevat järelevalvet.
English: Flucelvax Tetra contains proteins from four different inactivated influenza A and B virus strains (type A-H1N1, type A-H3N2 and two type B strains), chosen based on the official recommendation for the annual flu season.
Estonian: Flucelvax Tetra sisaldab A- ja B-gripiviiruse nelja erineva inaktiveeritud tüve valke (tüüp A-H1N1, tüüp A-H3N2 ja kaht B-tüübi tüve), vastavalt aasta gripihooaja ametlikele soovitustele.
English: Other information about Flucelvax Tetra
Estonian: Muu teave Flucelvax Tetra kohta
English: Historically, seasonal flu vaccines have contained three strains of flu: one influenza A-H1N1 virus, one influenza AH3N2 virus, and one influenza B virus.
Estonian: Ajalooliselt on hooajalise gripi vaktsiinid sisaldanud gripiviiruse kolme tüve: üht tüübi A-H1N1 tüve, üht tüübi A-H3N2 tüve ja üht B-tüübi tüve).
English: Flucelvax Tetra is a vaccine used to protect adults and children from 9 years of age against influenza (flu).
Estonian: Flucelvax Tetra on vaktsiin, mida kasutatakse täiskasvanute ja vähemalt 9-aastaste laste kaitsmiseks gripi eest.
English: What is Flucelvax Tetra and what is it used for?
Estonian: Mis on Flucelvax Tetra ja milleks seda kasutatakse?
English: The viruses used to produce Flucelvax Tetra are grown in mammalian cells.
Estonian: Flucelvax Tetra valmistamiseks kasutatavaid viirusi kasvatatakse imetajarakkudes.
English: The other vaccine is based on Optaflu but contains the other B strain of Flucelvax Tetra.
Estonian: Teine vaktsiin põhineb Optaflul, kuid sisaldab Flucelvax Tetra muud B-tüve.
English: Flucelvax Tetra was compared with two comparator vaccines in 2 main studies.
Estonian: Flucelvax Tetrat võrreldi kahe võrdlusvaktsiiniga kahes põhiuuringus.
English: The immune system will then be able to respond more quickly when it is exposed to the virus again.
Estonian: Kui immuunsüsteem puutub viirusega hiljem uuesti kokku, tekivad organismis antikehad kiiremini.
English: Flucelvax Tetra is a vaccine.
Estonian: Flucelvax Tetra on vaktsiin.
English: For the full list of side effects and restrictions with Flucelvax Tetra, see the package leaflet.
Estonian: Flucelvax Tetra kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Flucelvax Tetra includes an additional B virus strain.
Estonian: Flucelvax Tetra sisaldab täiendavat B-viirusetüve.
English: Flucelvax Tetra is as effective as the comparator vaccines at stimulating immune responses against the 4 strains included in the vaccine in people from 9 years of age.
Estonian: Flucelvax Tetra on sama tõhus kui võrdlusvaktsiinid, tekitades immuunvastuse vaktsiinis sisalduva nelja tüve vastu vähemalt 9-aastaste inimestel.
English: Results showed that Flucelvax Tetra lead to similar levels of protective antibodies as the comparator vaccines in people from 9 years of age.
Estonian: Tulemused näitasid, et Flucelvax Tetra andis võrdlusvaktsiinidega sarnase antikehade sisalduse vähemalt 9-aastastel inimestel.
English: What are the risks associated with Flucelvax Tetra?
Estonian: Mis riskid Flucelvax Tetraga kaasnevad?
English: When a person is given the vaccine, the immune system recognises the virus proteins as ‘foreign' and makes defences against them.
Estonian: Vaktsiini manustamisel peab immuunsüsteem viirusevalke võõrasteks ja tekitab nende vastu antikehi.
English: Influenza is mainly caused by two kinds of influenza virus, known as influenza A and B. Each of these circulate as different strains and subtypes, which change over time.
Estonian: Grippi põhjustavad peamiselt kahte liiki gripiviirused, mida nimetatakse A- ja B-gripiviiruseks.
English: Together the comparator vaccines contain the four strains of influenza in Flucelvax Tetra.
Estonian: Võrdlusvaktsiinid sisaldavad kokku nelja Flucelvax Tetras kasutatavat gripiviiruse tüve.
English: Flucelvax Tetra contains proteins from the surface of four different strains of flu virus.
Estonian: Flucelvax Tetra sisaldab nelja erineva gripiviirusetüve pinnavalke.
English: Flucelvax Tetra is available as a suspension for injection in a pre-filled syringe.
Estonian: Flucelvax Tetra on vaktsiin, mida turustatakse süstesuspensioonina eeltäidetud süstlas.
English: An overview of Flucelvax Tetra and why it is authorised in the EU
Estonian: Ülevaade ravimist Flucelvax Tetra ja ELis müügiloa väljastamise põhjendus
English: How does Flucelvax Tetra work?
Estonian: Kuidas Flucelvax Tetra toimib?
English: What benefits of Flucelvax Tetra have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Flucelvax Tetra kasulikkus?
English: How is Flucelvax Tetra used?
Estonian: Kuidas Flucelvax Tetrat kasutatakse?
English: The inclusion of two influenza B strains in Flucelvax Tetra can provide a broader protection against influenza B. In terms of safety, side effects with Flucelvax Tetra are similar to those observed with vaccines containing three influenza strains and are mostly mild to moderate in severity.
Estonian: Ohutuse seisukohast on Flucelvax Tetra kõrvalnähud sarnased vaktsiinidega, mis sisaldavad kolme gripitüve ja on enamjaolt kerged kuni mõõdukad.
English: The composition of Flucelvax Tetra will be updated annually according to WHO and EU recommendations.
Estonian: aastal vastavalt Maailma Terviseorganisatsiooni ja Euroopa Liidu soovitustele.
English: Liprolog Mix is a mixture of these two formulations.
Estonian: Liprolog Mix on nende kahe vormi segu.
English: The full EPAR for Liprolog can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Liprologi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Liprolog is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Liprologi võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Liprolog?
Estonian: Mis meetmed võetakse, et tagada Liprologi ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Liprolog on 1 August 2001.
Estonian: Euroopa Komisjon andis Liprologi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 1. augustil
English: Studies also looked at the use of Liprolog in 542 patients aged between two and 19 years, and the use of Liprolog in combination with sulphonylureas.
Estonian: Uuriti ka Liprologi kasutamist 542 patsiendil vanuses 2-19 aastat ning Liprologi kasutamist koos sulfonüüluurearavimitega.
English: The Committee recommended that Liprolog be given marketing authorisation.
Estonian: Komitee soovitas anda Liprologi müügiloa.
English: Other information about Liprolog
Estonian: Muu teave Liprologi kohta
English: Liprolog insulin lispro
Estonian: Liprolog lisproinsuliin
English: Patients can inject themselves with this medicine if they have been trained appropriately.
Estonian: Kui patsiendid on saanud asjakohase väljaõppe, tohivad nad süstida seda ravimit endale ise.
English: Liprolog and Liprolog Mix are normally given shortly before a meal, but they can be given just after a meal if necessary.
Estonian: Liprologi ja Liprolog Mixi manustatakse tavaliselt vahetult enne sööki või vajaduse korral vahetult pärast sööki.
English: Liprolog was originally studied in eight clinical trials including 2951 patients with type 1 diabetes (when the body cannot produce insulin) or type 2 diabetes (when the body is unable to use insulin effectively).
Estonian: Liprologi uuriti algselt kaheksas kliinilises uuringus, milles osales kokku 2951 patsienti, kellel oli I tüüpi diabeet (organismis ei teki insuliini) või II tüüpi diabeet (organism ei ole suuda insuliini efektiivselt kasutada).
English: • Liprolog Basal: insulin lispro protamine suspension;
Estonian: • Liprolog Basal: lisproinsuliini protamiinisuspensioon;
English: LiprologLiprolog doses might need to be adjusted when given with other medicines that may have an effect on blood glucose levels.
Estonian: Liprologi annust võib olla vaja kohandada, kui seda võetakse koos muu ravimiga, mis võib mõjutada vere glükoosisisaldust.
English: This is a summary of the European public assessment report (EPAR) for Liprolog.
Estonian: See on ravimi Liprolog Euroopa avaliku hindamisaruande kokkuvõte.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Liprolog.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: What is Liprolog?
Estonian: Mis on Liprolog?
English: Diabetes is a disease in which the body does not produce enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Estonian: Diabeet (suhkurtõbi) on haigus, mille korral organismis ei teki vere glükoosisisalduse reguleerimiseks piisavalt insuliini või organism ei suuda insuliini efektiivselt kasutada.
English: Why has Liprolog been approved?
Estonian: Miks Liprolog heaks kiideti?
English: For more information about treatment with Liprolog, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Liprologiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: • Liprolog: insulin lispro solution, available in a standard or a higher strength (100 or 200 units/ml);
Estonian: • Liprolog: lisproinsuliini lahus, turustatakse standardse või suure tugevusega (100 või 200
English: Liprolog is a replacement insulin which is very similar to the insulin made by the body.
Estonian: Liprolog on asendusinsuliin, mis on väga sarnane organismis tekkiva insuliiniga.
English: The replacement insulin acts in same way as naturally produced insulin and helps glucose enter cells from the blood.
Estonian: Asendusinsuliin toimib samal viisil kui organismis looduslikult tekkiv insuliin, aidates glükoosil siseneda verest rakkudesse.
English: Liprolog is supplied in vials, cartridges and prefilled pens (Liprolog KwikPen).
Estonian: Liprologi turustatakse viaalides, kolbampullides ja eeltäidetud pensüstaldes (Liprolog KwikPen).
English: Liprolog may cause hypoglycaemia (low blood glucose levels) and must not be given to patients whose blood glucose is already low.
Estonian: Liprolog võib põhjustada hüpoglükeemiat (vere väike glükooosisisaldus) ja seda ei tohi võtta patsiendid, kelle vere glükoosisisaldus on juba väike.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Liprolog, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Liprologi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The studies measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled, and ‘fasting' blood glucose levels (measured when the patient had not eaten for at least eight hours).
Estonian: Uuringutel mõõdeti glükohemoglobiini (HbA1c) sisaldust veres, mis näitab, kui hästi reguleerib organism vere glükoosisisaldust, ja vere glükoosisisaldust tühja kõhu korral (kui söömisest oli möödunud vähemalt kaheksa tundi).
English: What is the risk associated with Liprolog?
Estonian: Mis riskid Liprologiga kaasnevad?
English: The Liprolog range is comprised of fast-acting insulin solutions (Liprolog), longer-acting insulin suspensions (Liprolog Basal), and combinations of both in various proportions (Liprolog Mix):
Estonian: Liprologi tootesari koosneb kiiretoimelisest insuliinilahusest (Liprolog), pikatoimelisest insuliinisuspensioonist (Liprolog Basal) ja mõlemat tüüpi eri suhtes sisaldavatest kombinatsioonidest (Liprolog Mix):
English: For the full list of all side effects and restrictions with Liprolog, see the package leaflet.
Estonian: Liprologi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The effectiveness of Liprolog was compared with that of Humulin R (a soluble recombinant DNA human insulin), when added to long-acting insulins given once or twice a day.
Estonian: Liprologi efektiivsust võrreldi ravimi Humulin R efektiivsusega (lahustuv rekombinant-DNAiniminsuliin): mõlemat ravimit lisati pika toimeajaga insuliinidele, mida manustati üks või kaks korda ööpäevas.
English: In addition, the company that makes Liprolog has provided information to patients and healthcare professionals to remind them that there are two strengths of Liprolog and to advise them on how to use them safely to avoid medication errors.
Estonian: Lisaks annab Liprologi tootja patsientidele ja tervishoiutöötajatele teabematerjalid, milles neile meenutatakse ravivigade ennetamiseks, et Liprologi turustatakse kahes tugevuses, ning selgitatakse nende ohutut kasutamist.
English: The active substance in Liprolog, insulin lispro, is produced by a method known as ‘recombinant DNA technology': it is made by bacteria into which a gene (DNA) has been introduced, which makes them able to produce insulin lispro.
Estonian: Liprologi toimeainet liproinsuliini valmistatakse rekombinant-DNA-tehnika abil: seda toodavad bakterid, millele on lisatud insuliini teket võimaldav geen (DNA).
English: The Committee for Medicinal products for Human Use (CHMP) decided that Liprolog's benefits are greater than its risks for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis, and for the initial stabilisation of diabetes mellitus.
Estonian: Inimravimite komitee otsustas, et Liprologi kasulikkus diabeediga ja glükoosi normaalse homeostaasi hoidmiseks ja diabeedi esialgseks stabiliseerimiseks insuliiniravi vajavate täiskasvanute ja laste ravis on suurem kui ravimiga kaasnevad riskid.
English: Liprolog 200 units/ml must only be injected under the skin, using the KwikPen device in which it is supplied.
Estonian: Liprologi tugevusega 200 ühikut/ml tohib manustada ainult nahaaluse süstega, kasutades KwikPen-pensüstalt, milles ravimit turustatakse.
English: Liprolog 100 units/ml may also be given by continuous infusion using an insulin pump or into a vein.
Estonian: Liprologi tugevusega 100 ühikut/ml tohib manustada ka veeni või pidevinfusioonina, kasutades insuliinipumpa.
English: Liprolog can be used with a longer-acting insulin or with sulphonylureas (a group of diabetes medicines that are taken by mouth).
Estonian: Liprologi tohib kasutada koos pika toimeajaga insuliiniga või sulfonüüluurearavimitega (teatud suukaudsed diabeediravimid).
English: What benefit has Liprolog shown during the studies?
Estonian: Milles seisneb uuringute põhjal Liprologi kasulikkus?
English: The difference means that insulin lispro is absorbed faster by the body than human regular insulin, and can therefore act faster.
Estonian: Lisproinsuliin erineb veidi iniminsuliinist, sest see imendub organismis kiiremini kui tavaline iniminsuliin, mille tõttu on ravimi toime kiirem.
English: Liprolog is used to treat patients who have diabetes and need insulin to keep their blood glucose (sugar) level controlled, including patients whose diabetes has just been diagnosed.
Estonian: Liprologi kasutatakse diabeediga patsientide, sealhulgas äsja diagnoositud diabeediga patsientide raviks, kes vajavad vere glükoosisisalduse reguleerimiseks insuliini.
English: Liprolog, Liprolog Basal and Liprolog Mix may be given by injection under the skin of the upper arm, thigh, buttock or abdomen (tummy).
Estonian: Liprologi, Liprolog Basalit ja Liprolog Mixi manustatakse nahaaluse süstena õlavarre, reie, tuhara või kõhu piirkonda.
English: How has Liprolog been studied?
Estonian: Kuidas Liprologi uuriti?
English: What is Liprolog used for?
Estonian: Milleks Liprologi kasutatakse?
English: Insulin lispro is available as Liprolog in the soluble form, which acts more or less immediately after injection, and as Liprolog Basal in the ‘protamine suspension' form, which is absorbed much more slowly so that it works for longer.
Estonian: Liprolog sisaldab lisproinsuliini lahustuval kujul, mis toimib peaaegu kohe pärast süstimist; Liprolog Basal sisaldab lisproinsuliini protamiinisuspensioonina, mis imendub palju aeglasemalt, nii et toime on pikaajalisem.
English: Liprolog Mix, Liprolog Basal and Liprolog 200 units/ml should never be given into a vein.
Estonian: Mitte kunagi ei tohi ravimeid Liprolog Mix, Liprolog Basal ja Liprologi tugevust 200 ühikut/ml manustada veeni.
English: Liprolog contains the active substance insulin lispro.
Estonian: Liprolog sisaldab toimeainena lisproinsuliini.
English: How is Liprolog used?
Estonian: Kuidas Liprologi kasutatakse?
English: The medicine can only be obtained with a prescription.
Estonian: Liprolog on retseptiravim.
English: Liprolog is a range of solutions and suspensions for injection.
Estonian: Liprolog on süstelahuste ja -suspensioonide tootesari.
English: Liprolog and Humulin R had a similar effect on the control of diabetes, as measured by HbA1c and fasting glucose levels.
Estonian: Glükohemoglobiini sisalduse ja tühja kõhu korral mõõdetud glükoosisisalduse põhjal selgus, et Liprolog ja Humulin R toime vere glükoosisisaldusele oli sarnane.
English: How does Liprolog work?
Estonian: Kuidas Liprolog toimib?
English: Regarding safety, the medicine's side effects are considered acceptable.
Estonian: Ohutusega seoses peeti ravimi kõrvalnähte vastuvõetavateks.
English: Further information on Venclyxto can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Venclyxto.
Estonian: Lisateave Venclyxto kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Venclyxto.
English: This was converted into a full marketing authorisation on 20 November 2018.
Estonian: Tingimuslik müügiluba muudeti tavaliseks müügiloaks 20. novembril 2018.
English: Venclyxto received a conditional marketing authorisation valid throughout the EU on 5 December 2016.
Estonian: Venclyxto on saanud müügiloa tingimusliku heakskiidu alusel, mis kehtib kogu ELis, 5. detsembril 2016.
English: What measures are being taken to ensure the safe and effective use of Venclyxto?
Estonian: Mis meetmed võetakse, et tagada Venclyxto ohutu ja efektiivne kasutamine?
English: The European Medicines Agency decided that Venclyxto's benefits outweigh its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Venclyxto kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Venclyxto is available as tablets (10, 50 and 100 mg) to be taken by mouth once a day with a meal.
Estonian: Venclyxtot turustatakse tablettidena (10, 50 ja 100 mg), mida võetakse suu kaudu üks kord ööpäevas koos söögiga.
English: By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down the progression of the disease.
Estonian: Bcl-2-ga seondudes ja selle toimet blokeerides põhjustab venetoklaks vähirakkude surma ning aeglustab sellega haiguse progresseerumist.
English: If the patient experiences certain side effects, treatment may be stopped temporarily or the dose reduced.
Estonian: Teatud kõrvalnähtude tekkimisel patsiendil võib ravi ajutiselt katkestada või annust vähendada.
English: As for all medicines, data on the use of Venclyxto are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Venclyxto kasutamise kohta pidevat järelevalvet.